MUMBAI, April 23 (Reuters) - Indian biotech firm Biocon Ltd has filed a prospectus for the initial public offering of its $600 million research and development arm, Syngene, it said on Thursday.
The company plans to sell 22 million shares, including an overallotment, it said in a statement, after the prospectus was filed with India's market regulator.
07:15 Telefonica to sell up to 40 percent of Telxius to KKR for 1.3 billion euros22
17:35 Boeing to open first European factory, to invest 20 million pounds22
12:53 Samsung Display gets license to invest $2.5 billion more in Vietnam: state TV17
09:14 Airbus seeks new talks with European nations over A400M costs17